



## Imugene granted Japanese patent for novel drug delivery technology

---

### Highlights

- Japan Patent Office officially grants key foundation patent application protecting Imugene's Linguet™ drug delivery technology
- Patent protects specific drug formulations targeting bone loss prevention

**Melbourne, 7 August 2013:** Australian drug delivery technology company Imugene (ASX:IMU) has announced today the official granting of a key Japanese patent application for the Company's novel drug delivery technology Linguet™ (patent no: 5256425), following on from an earlier allowance in March 2013.

The Japanese patent provides protection around Linguet's™ formulations and other specific excipients for a class of drugs that prevent the loss of bone mass, known as bisphosphonic acids and bisphosphonates, which are used to treat conditions such as osteoporosis and multiple myeloma.

It is projected that more than about 50% of all osteoporotic hip fractures will occur in Asia by the year 2050. The prevalence of osteoporosis in the Japanese female population aged 50-79 years has been estimated to be about 35% at the spine and 9.5% at the hip (source: <http://www.iofbonehealth.org/facts-statistics>).

Linguet is now protected in two key markets, with the same patent formulation granted in China in May 2013.

Imugene uses its proprietary drug delivery technology to improve the efficacy and safety of a diverse number of existing prescription and over the counter medicines. Its platform technology, known as Linguet™, enables the active ingredient of drugs to be absorbed straight into the bloodstream when placed inside the cheek (via the buccal mucosa) or under the tongue (sublingual).

"The expansion of our patent portfolio in both Japan and China is a significant step in our commercialisation strategy. Not only does it demonstrate the strength of our novel Linguet technology, but it enables us to explore two lucrative Asian markets for licensing opportunities in the billion dollar bisphosphonate market for osteoporosis," said Dr Nick Ede, Executive Director of Imugene.

- Ends -

For personal use only

**For investor enquiries please contact:**

**Dr Nick Ede, Imugene – 0400 642 254 / [nede@imugene.com](mailto:nede@imugene.com)**

**About Imugene**

Imugene Limited (ASX:IMU) is commercialising drug delivery applications based on its novel buccal (drugs administered via the cheek) Linguet™ technology. Linguet™ is a patient friendly and cost effective system used to deliver established pharmaceutical and nutraceutical products.

For personal use only